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Abstract Analgosedation is a fundamental part of traumatic
brain injury (TBI) treatment guidelines, encompassing both
first and second tier supportive strategies. Worldwide
analgosedation practices continue to be heterogeneous due
to the low level of evidence in treatment guidelines (level
III) and the choice of analgosedative drugs is made by the
treating clinician. Current practice is thus empirical and may
result in unfavourable (often hemodynamic) side effects. This
article presents an overview of current analgosedation prac-
tices in the paediatric intensive care unit (PICU) and addresses
pitfalls both in the short and long term. We discuss innovative
(pre-)clinical research that can provide the framework for ini-
tiatives to improve our pharmacological understanding of an-
algesic and sedative drugs used in paediatric severe TBI and
ultimately facilitate steps towards evidence-based and preci-
sion pharmacotherapy in this vulnerable patient group.
Keywords Traumatic brain injury . Paediatric . Analgesia .
Sedation . Pharmacology
Introduction
The main goal of (paediatric) TBI treatment is the provision of
supportive care to guarantee adequate cerebral perfusion to
meet cerebral metabolic demands and limit secondary brain
injury [1, 2]. Appropriate management is critical as paediatric
TBI still causes major morbidity and mortality worldwide [3,
4]. One of the cornerstones in severe paediatric TBI treatment
is providing analgesia and sedation; however, current research
efforts have not provided any level 1 evidence to support a
specific regimen. This has resulted in the international 2012
TBI guideline recommendation that: ‘the choice of and dosing
of sedative, analgesics …. should be left to the treating phy-
sician..’ [5]. This leads to heterogeneous analgosedation pre-
scribing practices based on local expertise and guided by
(hemodynamic) side effects which can lead to both over and
under sedation. Furthermore, it seems that exposure to certain
analgosedation drugs might lead to neurotoxic injury and
could be associated with unfavourable outcome in the long
term (e.g. radiographic decrease in brain mass, learning dis-
abilities), especially in the developing paediatric patient [6–8].
Although it is difficult to differentiate between the sequelae of
primary vs. secondary brain injury, such observations neces-
sitate better pharmacological understanding to achieve both
effective and safe analgesia and sedation. To that end, it is
important to gain insight into the pharmacokinetics (PK; i.e.
‘what the body does to the drug’) and the resulting pharmaco-
dynamics (PD; i.e. ‘what the drug does to the body’) of fre-
quently used analgosedative drugs. It should be noted that
plasma PK may differ substantially from brain target site PK
due to the functionalities of the blood-brain-barrier (BBB) and
the blood-cerebrospinal fluid barrier (BCSFB) [9] and infor-
mation on drug target site distribution is essential to under-
stand PK-PD relationships in different TBI disease states.
Collaboration between preclinical and clinical research is
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essential in this respect. Techniques such as high-frequency
multimodal neuromonitoring, including cerebral microdialy-
sis, combined with advanced PK-PDmodelling are promising
tools [10, 11]. The physiologically based (PB) pharmacoki-
netic (PBPK) modelling approach is particularly useful as it
allows translation from animals to humans. Measurements
that cannot be performed (or only highly limited) in humans
can be performed in animals, and the resulting data can be
physiologically scaled to predict PK in humans. This is im-
perative to fully understand how drugs behave in the body and
vice versa. This improved pharmacological understanding
will facilitate development of more patient-specific treatment
strategies in a heterogeneous condition like paediatric TBI,
which requires a tailored approach to achieve effective and
safe therapy. This narrative review aims to provide an over-
view of current practice and its potential pitfalls and discusses
possibi l i t ies of developing more evidence-based
analgosedation practices in paediatric TBI.
Methods
A literature search was performed using search strategies with
MeSH terms and synonyms of ‘brain injury’, ‘analgesia’, ‘seda-
tion’ and ‘children’ with the search databases Embase, Ovid,
Cochrane Central, Web of Science and Google Scholar. A total
of 1160 potential references were found that were reviewed by
the primary author for relevance based on the aim to provide a
pharmacological overview of paediatric severe TBI
analgosedation practice and principles. Additional references
were added by cross-reference check. It must be emphasized that
the 2012 international guidelines for paediatric TBI management
remain the mainstay of treatment recommendations [5]. This
article provides additional pharmacological background informa-
tion and highlights novel approaches in pharmacological
research.
Practice
The application of analgesia and sedation in the stabilisation
and (supportive) treatment of paediatric severe TBI occurs in
various settings from the scene of the accident, emergency
department, perioperatively and after admission and stay in
the paediatric intensive care unit (PICU). The primary aim
for administering analgosedation is to lower cerebral metabol-
ic demand which can be increased by anxiety, stress and pain
induced by the primary trauma and further exacerbated by
noxious stimuli such as (invasive) procedures and invasive
ventilation [2, 12–14]. This article will focus on
analgosedation practices in the PICU. The ideal properties of
analgosedation drugs in paediatric severe TBI would be to
induce an immediate analgesic and/or sedative effect without
negatively affecting hemodynamic stability or intracranial
pressure (ICP) and have rapid offset of action to enable neu-
rological examination. The compound should also be safe in
the long term with respect to neurotoxicity. Many frequently
used compounds offer some of the aforementioned character-
istics, but none have so far demonstrated all favourable ele-
ments. Perhaps, this is not possible given the physiological
and developmental differences between patients from ages 0
to 18 years and the heterogeneous nature of brain injury itself.
Most PICUs adopt a TBI protocol based on international
guidelines, consensus and local variations in practice. The
provision of sedation and analgesia is subdivided in so-
called first and second tier therapies in a step-up approach to
control ICP and maintain adequate cerebral perfusion pressure
(CPP) [5, 15]. Adherence to local protocols with respect to
analgosedation varies based on personal preference and
patient-specific factors. A survey in the USA explored physi-
cian agreement with published recommendations and guide-
lines for paediatric TBI showed a 91% agreement with first-
tier sedation recommendations and a 89% agreement with the
use of barbiturates as second tier therapy. However, no spec-
ification was provided as to which agents were used when
providing analgosedation [16]. One study, which audited its
analgosedation practice, reported a 64% adherence to their
written protocol with patient-specific adjustments in 30% of
these cases [17]. This illustrates the variation in
analgosedation practice for paediatric TBI, which is not sur-
prising given the lack of evidence-based regimen.
Analgesic compounds described in the literature for paedi-
atric severe TBI are opioids (Fentanyl, Remifentanil,
Morphine), Acetaminophen and Metamizole [12, 17–20].
Sedative compounds include benzodiazepines (Midazolam,
Lo r a z e p am , D i a z e p am ) , Ke t am i n e , P r o po f o l ,
Dexmedetomidine and Etomidate [12, 14, 17, 18, 21].
Barbiturates (Thiopental and Pentobarbital) are part of second
tier therapeutic strategies for lowering refractory intracranial
hypertension under electroencephalogram (EEG)-monitoring
to ascertain burst-suppression [2, 12, 14, 18, 22–24]. Tables 1
and 2 provide an overview of the pharmacological properties
of the various analgosedative drugs (only Food and Drug
Administration (FDA) approved drugs included).
Most commonly, a combination of an analgesic and sedative
drug is prescribed as a continuous infusion with a step-up ap-
proach in dosing based on clinical effect (often a combination of
neurological exam, ICP-threshold, and pain and sedation scoring
systems). The sedative effect of most analgesic compounds dur-
ing dose escalation is often an added benefit in ICP control [14].
Additional bolus medication is common to combat prolonged
ICP elevation and determine if pain could be a possible cause
thereof [14]. Reports indicate that Fentanyl andMidazolam (sep-
arately or in conjunction) are mostly used as bolus
analgosedation. Various studies have been performed to clarify
which bolus medications are most effective to lower high ICP
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and present conflicting and sometimes paradoxical results [25].
The benefit of Ketamine for episodic use during potential nox-
ious stimuli (e.g. endotracheal tube suctioning) is that it does not
decrease blood pressure and could be a valuable adjuvant for
interventions [26]. However, historically, this compound has
been avoided as it was associated with an increase in ICP
[27–29]. Recent paediatric studies using (racemic) Ketamine as
bolus medication for episodes of sustained ICP elevation dem-
onstrate its effect in lowering intracranial hypertension [18].
Adult studies show similar findings and support its use when
combined with Midazolam [30]. Remifentanil has been shown
to be an effective analgesic drug (mostly demonstrated in the
adult critical care setting) due to its rapid onset and offset of
action enabling frequent, serial neurological examinations [19,
20, 31]. Barbiturates (Thiopentone and Pentobarbital) are imple-
mented as second tier therapy to control refractory intracranial
hypertension and have been shown to be effective in reducing
ICP in the paediatric population in 30–52% of patients [23, 32].
Dexmedetomidine is gaining increasing interest as a sedative
agent in the PICU due to its limited side effects although the
majority of publications are based on postoperative cardiac pa-
tients. It has been approved by the FDA for sedation <24 h in
adults with invasive ventilation and there are reports of its use in
the PICU for severe TBI patients (who went on to have good
neurological outcomes) and it has been reported to have a opioid-
sparing effect in PICU patients requiring sedation [21, 33].
Finally, a brief word on neuromuscular blockade (NMB) is war-
ranted as this is combined with analgosedation in first-tier strat-
egies to reduce energy expenditure (e.g. shivering) and improve
mechanical ventilation synchronization. Again no class I evi-
dence for NMB is available but it is imperative that at the same
time continuous electroencephalography is implemented when
continuous NMB infusion is used to determine the presence of
posttraumatic seizures [5, 14, 34].
Table 1 Overview analgesic drugs in paediatric severe traumatic brain injury
Class Medication Mode of action Dosage T ½ Side effects PK points of interest
Opioid Morphine Opiate receptor agonist Bolus 0.05–0.1
mg/kg
2–4 h Respiratory depression,
hypotension, urinary
retention, vomiting,
constipation, pruritus
Active metabolite
morphine-6-glucuronide (M6G)
Range 0.01–0.04
mg/kg/h
Direct interaction with opioid binding
sites in brain
Active efflux mechanism in brain
(P-glycoprotein and multidrug
resistance-associated protein
(MRP)) and active influx transporter
(undefined)
Fentanyl Opiate receptor
agonist: inhibition
of nociceptive
neurotransmitters
Bolus 1–2
mcg/kg
7 h Sedation, respiratory
depression,
hypotension, muscle
rigidity (thorax), nausea
High lipophilicity leading to easier
penetration CNS. Not subjected to
active transport across the BBB
Range 1–2
mcg/kg/h
Remifentanil Opiate (specific)
mu-receptor agonist
Bolus 0.25–1
mcg/kg
1–20 min Respiratory depression,
muscle rigidity,
hypotension, nausea,
pruritus
Direct interaction with opioid binding
sites in brain
Ultra-rapid onset and
offset of action
Range 0.1–2
mcg/kg/min
Other Acetaminophen Inhibition of
cyclooxygenase
(COX) enzymes
involved in
prostaglandin
synthesis
Loading dose
20 mg/kg i.v.
1–4 h Risk of hepatic necrosis
and failure in
prolonged or high
dosage
Blockage of COX enzymes in the CNS
Maintenance
60 mg/kg/dg
in 4 doses
(maximum
1 g per dose)
The abovementioned dosage suggestions are for children aged 0–18 years of age, with the exception of neonates (<1 month old)
BBB blood-brain-barrier, COX cyclooxygenase, CNS central nervous system, i.v. intravenous, MRP multidrug resistance-associated protein, PK
pharmacokinetic
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At this point, it needs to be noted that ‘efficacy’ of
analgosedation is often titrated solely on the effect of ICP-
and CPP-control and clinical signs of agitation. However,
there is increased awareness that there are additional factors
which need to be considered to develop a holistic picture of
risk factors for secondary injury that could serve as pharma-
codynamic (PD) markers in analgosedation studies.
Multimodal neuromonitoring seems especially important
Table 2 Overview sedative drugs in paediatric severe traumatic brain injury
Class Medication Mode of action Dosage T ½ Side effects PK points of
interest
Benzodiazepine Midazolam GABA receptor
agonist
Bolus
0.05–0.2
mg/kg
5.5 h
(±3.5 h)
Sedation, respiratory
depression,
hypotension,
bradycardia,
(paradoxical)
emergence delirium
Metabolized to
active
metabolites
1- and
4-hydroxy-
midazolam
Range
0.05–0.5
mg/kg/h
Lipophilic
Barbiturate Pentobarbital GABA receptor
agonist
Bolus 5 mg/kg 5–50 h (dose
dependant)
Sedation, respiratory
depression,
hypotension,
laryngospasm,
anaphylactic
reactions have
been reported
Lipophilic
Range
1–2 mg/kg/h
Thiopental GABA receptor
agonist
Range
12,5 mg/kg/h
(starting dose
for 6 h), then
5 mg/kg/h
and taper to
3 mg/kg/h
depending
on EEG and
plasma
concentration
3–8 h Sedation, respiratory
depression,
hypotension, skin
reactions (due to
histamine release),
laryngo- and
bronchospasm
Lipophilic
Other Propofol GABA receptor
agonist
Bolus 1–2 mg/kg 2–10 min
(initial
distribution
phase)
Hypotension,
respiratory
depression,
hypertriglyceridemia,
PRIS
Lipophilic
Range (not
recommended
but reported
up to 4
mg/kg/h)
Dexmedetomidine Selective
alpha-2-adrenoreceptor
agonist
Range 0.1–2
mcg/kg/h
(loading dose
0.25 mcg/kg
optional)
2 h Hypertension,
bradycardia
Lipophilic
Ketamine N-methyl-D-aspartate
receptor antagonist
Bolus 1–2
mg/kg
2.5–3 h Laryngospasm,
tachycardia,
dysphoria
Lipophilic
Etomidate GABA receptor
agonist
Bolus 0.3–0.5
mg/kg
75 min Adrenal insufficiency,
hypertension,
laryngospasm,
dyskinesia
Lipophilic
The abovementioned dosage suggestions are for children aged 0–18 years of age, with the exception of neonates (<1 month old)
EEG electroencephalogram, GABA gamma-aminobutyric acid, PK pharmacokinetic, PRIS propofol infusion syndrome
1706 Childs Nerv Syst (2017) 33:1703–1710
when defining clinical parameters of therapeutic efficacy. PD
markers of effective drug therapy could include cerebral oxy-
genation (PbtO2), cerebral metabolic state (cerebral microdi-
alysis yielding information on lactate and pyruvate) and brain
activity as monitored by continuous electroencephalogram
(EEG) [10]. Furthermore, it might be beneficial to differenti-
ate between patients with or without intact cerebral autoregu-
lation as certain drugs could actually induce an ICP increase
(and CPP decrease) when cerebral autoregulation is preserved
[35, 36]. In this respect, the time from initial injury can also be
an important factor, resulting in a different response of the
brain to analgosedative drugs over time.
Pitfalls
The potential negative effects of commonly used
analgosedative drugs can be subdivided into short- and long-
term pitfalls. Short-term pitfalls mostly refer to undesirable
hemodynamic side effects, i.e. a decrease in mean arterial
blood pressure (MAP) resulting in a decrease in cerebral per-
fusion pressure (CPP), which can further exacerbate second-
ary brain injury. Potential pitfalls based on specific drug or
patient characteristics are summarized in the following para-
graph. A more extensive overview of side effects is provided
in Tables 1 and 2.
Continuous infusion of Propofol is associated with
Propofol infusion syndrome (PRIS), which is characterized
by the onset of metabolic acidosis, rhabdomyolysis, acute re-
nal failure, cardiac dysthythmias and hyperlipidemia [37, 38].
Although there is evidence that continuous Propofol infusion
<4 mg/kg/h for periods >48 h can be safe [39, 40], the cost-of-
error is deemed so great that the FDA recommends withhold-
ing from continuous Propofol infusion in paediatric TBI [41].
As for bolus medication, Propofol is sometimes briefly used
as an adjuvant for procedural sedation. However, it is note-
worthy that delayed posttrauma administration of Propofol
could be associated with induction of apoptosis due to in-
creased expression of the P75 neurotrophin receptor, sensitiz-
ing the brain for neurotoxic effects in juvenile neurons [42].
Etomidate could be useful as bolus therapy for intracranial
hypertension episodes due to its favourable hemodynamic
profile [43]; however, its use is often restricted to intubation
settings due to the association with adrenal insufficiency [2].
Thiopental can potentially cause life-threatening electrolyte
imbalances, especially regarding potassium [44].
Dexmedetomidine has been reported to induce hypertension
at high-dose infusion (>4 μg/kg/h) for several hours [45].
Other reports have noted the occurrence of bradycardia, which
is more pronounced when this agent is combined with other
medications that yield a negative chronotropic effect [21].
Metamizole is frequently used as a non-opioid first-line anal-
gesic for adults in many countries but there are still many
controversies about potential risks (like agranulocytosis),
leading to a ban by the FDA. A recent systematic review
and meta-analysis showed that Metamizole is safe (no reports
of agranulocytosis) for short-term use in hospital [46].
Although its role in paediatric analgesia is unclear, it is report-
edly used in certain countries [17]. Various studies have dem-
onstrated that opioids could potentially increase ICP in TBI
patients with preserved cerebral autoregulation in conjunction
with systemic effects of mean blood pressure decrease. This
effect was most pronounced for Fentanyl [36, 47].
Furthermore, a recent study on the effectiveness of pharmaco-
logical therapies for intracranial hypertension demonstrated
that Fentanyl was significantly associated with frequent treat-
ment failure when compared to Pentobarbital and hypertonic
saline [48]. Fentanyl and Midazolam as bolus therapies for
intermittent intracranial hypertension have been associated
with ICP increase and CPP reduction [35].
Spreading depolarizations present a potential threat to func-
tional neurons, resulting in necrosis or degeneration and pos-
sibly poor outcome after brain injury. Analgosedation acts by
influencing neuronal homeostasis and has been investigated
for preventing or propagating spreading depolarizations. One
study found that N-methyl-D-aspartate (NMDA) receptor ag-
onists (such as Ketamine) led to less spreading depolariza-
tions, but Midazolam increased the amount of spreading de-
polarization clusters. These findings need to be investigated
further but provide an interesting angle into pitfalls and pos-
sibilities of these drugs [49]. Finally, it must be emphasized
that the severe TBI patient is often subject to polypharmacy
(i.e. multiple drugs being prescribed concurrently). It is im-
portant to be aware of drug-drug-interactions, which can lead
to subsequent undesirable effects. For example, the proton-
pump inhibitor Esomeprazole is frequently prescribed in crit-
ically ill patients. It has been reported that prescribing
Esomeprazole increases the volume of distribution and half-
life of Thiopentone, which needs to be taken into account
when aiming for certain target concentrations [50].
Long-term pitfalls have been described in the context of
(major) withdrawal symptoms and delirium, which obscure
adequate neurological evaluation. This suggests not only the
need for dose escalation in the acute phase of patient
stabilisation but also the development of guidelines to opti-
mally taper analgosedation afterwards [51]. Validated tools to
assess withdrawal symptoms (which can already occur after 5
consecutive days of opioid and/or benzodiazepine administra-
tion) and delirium in the PICU are theWithdrawal Assessment
Tool version 1 (WAT-1) and Sophia Observation withdrawal
Symptoms-Paediatric Delirium scale (SOS-PD) [52, 53].
Pharmacogenetics can be considered part of patient-
specific pitfalls. Important examples are so-called ABCB1
polymorphisms, which encode for P-glycoprotein transporter
that is responsible for morphine efflux over the blood-brain
barrier. This can result in different cerebral morphine
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concentrations and associated (prolonged) effect. The latter
has mostly been investigated in the context of prolonged re-
spiratory depression after opioid administration during elec-
tive procedures [54, 55].
Finally, there are concerns about the potential neurotoxic
apoptotic effects of certain drugs, especially in the developing
brain. Animal studies have demonstrated mechanisms by
which analgosedative agents of different classes (which are
also used in the PICU for TBI) trigger upregulation of apopto-
tic cerebral cascades (i.e. blocking of glutamate NMDA re-
ceptors, activation of gamma-aminobutyric acid (GABA), re-
ceptors or blocking of voltage gated sodium channels). This
results in inactivation of cell survival signalling proteins and
activation of inflammatory cytokines [7]. Furthermore, anaes-
thetic opioid exposure in animals showed a possible neurotox-
ic effect as demonstrated by elevated levels of S100B, a bio-
marker of brain injury [56]. It is of interest that these effects in
animals and cultured neuronal cells were dose dependant and
dependant on the maturity of neuronal tissue [57]. Studies in
preterm infants exposed to Fentanyl suggest that a higher cu-
mulative dose correlated with an increased incidence of cere-
bellar injury and lower cerebellar size when compared at term
equivalent age [6]. However, the results from paediatric gen-
e r a l ana e s t h e s i a s t ud i e s eva lua t i ng long - t e rm
neurodevelopmental outcome are more difficult to interpret
as these are heterogeneous populations often with a pre-
existing condition (e.g. congenital defect) giving rise to an a
priori increased risk of deficits in neurological development
[8, 58]. Of course extrapolation of preclinical and paediatric
anaesthetic clinical study findings to analgosedation practices
in paediatric TBI should be done with caution, despite the use
of similar compounds. However, these observations are im-
portant as they emphasise the necessity to search for both
effective and safe analgosedation dosing strategies in paediat-
ric TBI.
Possibilities
To date, current approaches have not been able to conclusively
yield the desired answers, i.e. which drugs are safe and effec-
tive to prescribe in (paediatric) TBI? The high failure rate in
CNS drug development and research can in part be attributed
to the fact that ‘golden standard’ approaches, such as random-
ized controlled trials (RCTs) and comparative effectiveness
designs, fail to take into account the heterogeneity of the dis-
ease process and drug- and patient-specific characteristics. In
particular, the unique functionality of the blood-brain and
blood-cerebrospinal (CSF) barrier, and therewith drug trans-
port into and out of the brain, are not elucidated. Thus, drug
target site concentration (e.g. cerebral drug concentrations) are
unknown. Information on the target site concentrations is fun-
damental in understanding drug action. Therefore, assessing
target site pharmacokinetics is the primary step before
attempting to study the resulting pharmacodynamics [9, 11,
59].
Bottlenecks in pharmacological research, especially in chil-
dren, are ethical concerns about performing invasive studies
of compounds with unproven benefit in minors, and difficulty
obtaining adequate sample size to provide definitive answers.
Another obstacle in paediatric drug research is the limited
number and volume of blood or cerebral fluid samples which
can be obtained per patient due to smaller circulating volumes.
This is where ‘bench-meets-bedside’ research can be of value.
Animal-based PBPK models can be translated to humans and
thereby serve as templates of what happens to a drug in the
body under various clinical conditions. After translation of the
animal PBPK model to humans, full drug concentration PK
profiles in human brain can be predicted. The PBPK human
model can be validated by comparing predicted drug concen-
tration values to a number of observed drug concentrations in
the human CNS (e.g. CSF and brain extracellular fluid from
microdialysis monitoring). Especially for paediatric PK anal-
ysis, obtaining individual plasma PK is crucial to predict a
drug concentration time profile in the CNS due to the various
developmental differences that have an impact on PK profiles.
Collecting sufficient human samples can be challenging, but
‘sparse sampling population-based PK (PPK) analysis’ is an
innovative statistical technique that can be used to solve this
challenge. Practically, this model requires only a limited num-
ber of samples per patient. The samples of various patients are
then used as a single ‘population’ (after corrections of covar-
iates such as age, weight, renal function) providing enough
data points to compile drug-specific pharmacokinetic time
profiles under different clinical conditions and developmental
differences. In other words, the combination of PBPK and
PPK modelling allows prediction of drug concentrations at
various target sites (e.g. blood plasma, brain extracellular flu-
id) at different dosing regimens for each paediatric patient. It
has been enlightening that drug plasma concentrations do not
represent cerebral drug concentrations, highlighting the
unique properties of the blood-brain and blood-cerebrospinal
fluid barrier [11, 59–61].
Although focus must shift ‘back to basics’ with regard to
improved pharmacological understanding of frequently used
analgesics and sedatives, this does not mean observations
from the clinical field should be dismissed. For example, com-
parative effectiveness research could provide direction as to
which drug compounds warrant further PK-PD research.
Finally, pharmacology is dynamic, complicated and an indis-
pensable part of clinical practice. It is imperative we under-
stand basic principles but also cooperate with experts in the
field to optimize our treatment. In this respect, a clinical phar-
macologist or hospital pharmacist can be of great value to
point out significant drug interactions and provide alternative
options as well as dose adjustments based on clinical status. It
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is becoming increasingly clear that a multifactorial, complex
disease like (paediatric) severe TBI warrants a multidisciplin-
ary approach, also as regards pharmacology.
Conclusion
Analgosedation is a crucial part of severe (paediatric) TBI
management but evidence-based guidelines are not available
leaving the choice of analgesic and sedative drugs to the
treating physician. Practice is heterogeneous and leads to se-
rious concerns about efficacy and safety. Pitfalls, besides the
well-known side effects of frequently used drugs, include
paediatric-specific concerns in terms of potential neurotoxici-
ty in the developing brain and age-specific differences in drug
distribution and metabolism. Possibilities to enhance our
pharmacological understanding include the implementation
of animal-based pharmacokinetic models that enable predic-
tion of drug concentrations at target sites. This combined with
multimodal neuromonitoring can link cerebral drug concen-
trations to drug effect and ultimately lead to more evidence-
based analgosedation therapies in (paediatric) TBI.
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